[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630136":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":72,"collaborators":75,"id":80,"slug":10,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":10,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":10,"studyType":92,"phases":10,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":105,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HEM-SURVIVE Structured Follow-up Mode",null,"Implementation of a structured follow-up system based on exposure-oriented risk stratification (four levels: Minimal, Standard, High, and Ultra-high risk). It includes standardized examination packages (A, A+, B, and C), multidisciplinary (MDT) survivor clinics, and digital management via the HEM-SURVIVE APP.",{"label":13,"type":10,"description":14,"interventionNames":10},"Conventional Follow-up Mode","Routine follow-up practices currently used in China. Examination projects are determined empirically by the attending physician and family, which lacks a unified path and systematic proactive monitoring. Key examinations for late effects are often triggered only after symptoms appear.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Jingying Zhang, MD","CONTACT","+86 571 86670076","zhangjy423@zju.edu.cn",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Tian Xia, MD","+86 15267035696","xiatian0604@zju.edu.cn",[26,46,58],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Children's hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000","China",{"type":33,"coordinates":34},"Point",[35,36],120.16142,30.29365,{"lat":36,"lon":35},[39,42,44],{"name":40,"role":18,"phone":41,"phoneExt":10,"email":20},"Jing ying Zhang, MD","86-15968103802",{"name":22,"role":18,"phone":43,"phoneExt":10,"email":24},"86-15267035696",{"name":40,"role":45,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":47,"status":10,"city":28,"state":29,"zip":48,"country":31,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Hangzhou Children's Hospital","310014",{"type":33,"coordinates":50},[35,36],{"lat":36,"lon":35},[53,55,56],{"name":54,"role":18,"phone":41,"phoneExt":10,"email":20},"Jing Huang, MD",{"name":22,"role":18,"phone":43,"phoneExt":10,"email":24},{"name":54,"role":57,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":59,"status":10,"city":60,"state":29,"zip":61,"country":31,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Affiliated Women and Children's Hospital of Ningbo University","Ningbo","315000",{"type":33,"coordinates":63},[64,65],121.54945,29.87819,{"lat":65,"lon":64},[68,70,71],{"name":69,"role":18,"phone":41,"phoneExt":10,"email":20},"Jian hua Feng, MD",{"name":22,"role":18,"phone":43,"phoneExt":10,"email":24},{"name":69,"role":57,"phone":10,"phoneExt":10,"email":10},{"type":45,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"zhangjingying","Principal Investigator",[76,78],{"name":77,"class":6},"Ningbo Women & Children's Hospital",{"name":47,"class":79},"UNKNOWN","100630136",false,"NCT07483749","HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors","A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)","Inclusion Criteria:\n\n* Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.\n* Age 1-21 years.\n* Capable of completing follow-up and data collection.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Severe organ failure preventing follow-up.\n* Major genetic or systemic diseases affecting growth\u002Forgan function.\n* Expected poor compliance or refusal to participate.","ALL","1 Year","21 Years",{"count":90,"type":91},400,"ESTIMATED","OBSERVATIONAL","This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.",[95,96,97,98,99],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Lymphoma","Leukemia","Pediatric",[101,102,103,104],"Survivorship","Late Effects","Follow-up Model,","Risk Stratification","NOT_YET_RECRUITING","2026-03-17",{"date":108,"type":109},"2026-03-19","ACTUAL",{"date":111,"type":91},"2026-03-25",{"date":113,"type":91},"2028-12",{"name":5,"class":6},3]